Background and Objectives
Chlamydia trachomatis is an important cause of morbidity and mortality in women and neonates. [1] It is commonly associated with cervicitis, pelvic infl ammatory disease (PID) and infertility. Pregnancy complications, including ectopic pregnancy, premature delivery, low birth weight, stillbirths and neonatal death have been cited in the literature.
Other pregnancy complications include premature rapture of membranes, gestational bleeding, amnionitis, neonatal and puerperal infections. [3] Up to 80% of women and 50% of men infected by C. trachomatis infections are asymptomatic, which makes clinical diagnosis of C. trachomatis infections diffi cult. [4] Women with cervical chlamydia infection at the time of delivery have 60-70% chance of transmitting the infection to the infant, [5] which may result in neonatal conjunctivitis in 35-50% of cases and neonatal pneumonia in 10-20% of cases. [6, 7] Screening for chlamydia infection in pregnant women is, therefore, a high public health priority. However, due to resource limitations in developing countries, chlamydia infection in pregnant women is not routinely screened. Diagnosis is limited to syndromic approach, a diagnostic strategy whose sensitivity and specifi city are very low. [8] Available reference methods for the diagnosis of C. trachomatis infection including isolation cell culture, direct fl uorescent antibody (DFA), enzyme immunoassay (EIA), nucleic acid probe (NAP) tests, including the APTIMA Combo 2 Assay, nucleic acid amplifi cation test (NAAT). [7, 9] However, these tests have limited utility in developing countries because of costs and long turnaround times. [10, 11] For example the cost of the Becton Dickinson (BD) ProbeTec TM ET Chlamydia trachomatis amplifi ed DNA assay for detecting C. trachoatis at the time of this study was US$10.00 per sample on a cost per test model. Therefore, rapid antigen detection tests or Point of Care (POC) tests are preferred in developing countries.
Rapid antigen tests use monoclonal antibodies in immunochromatographic strips to capture and detect chlamydial antigens from endocervical swabs. They require less expertise and give results within 30 minutes. [12] Their sensitivities, against Polymerase Chain Reaction (PCR) range between 49.7% and 95%, while their specifi cities between 97.9% and 100%. [13] [14] [15] [16] 
METHODS

Study setting
Mbare is a densely populated suburb in Harare, Zimbabwe with an estimated population of 300,000 people. Mbare Polyclinic, is a primary health care facility in Mbare. This study was conducted at Mbare Polyclinic's antenatal clinic (ANC). The clinic has three days set aside for women attending their fi rst ANC visits during the week one day for repeat visits.
Study design
This was a cross sectional experimental study in pregnant women attending fi rst ANC visit at Mbare Polyclinic.
Study population and sample size
The target population were pregnant women 18 years or older attending ANC visits between January and April 2012. Eligible women should not have received erythromycin, azithromycin, or amoxicillin within the previous one month. A total of 242 consenting met the selection criteria and were included in the study.
Chlamydia trichomitis detection using Cortez OneStep Chlamydia RapiCard TM insta test
This is a rapid immunoassay for direct qualitative detection of Chlamydia trachomatis antigen from endocervical or endourethral swab specimens. The assay is based on chemical extraction of a carbohydrate antigen from C. trachomatis followed by qualitative detection of C. trachomatis utilization using migratory colour immuno-assay technology. The test takes about 20 minutes.
Extraction buffer A was mixed by swirling and six drops of the buffer were added to each of the labelled test tubes. Patient swab specimens were placed in the test tubes and swirled briefl y to mix the sample with the buffer. The swabs were incubated for 5 minutes at 25°C. Thereafter, 6 drops of Extraction Buffer B were added to each of the test tubes. The swabs were twirled vigorously for 10 seconds and removed from the test tubes. The swabs were discarded after all the liquid was removed from the swabs by pressing the swabs against the test tube walls. The test tubes were recapped and further mixed by gently swirling the tubes. Seven drops of the swab extract were dispensed into the sample wells of the test device. The results were read after 15 minutes and recorded on the patients' laboratory request forms.
A positive result was interpreted as two rose pink bands appearing after 15 minutes, one in the control zone and another in the test zone indicating the presence of C. trachomatis antigen in the sample. One rose pink band in the control zone indicated a negative result. No pink band in the control zone with or without a pink band in the test zone was interpreted as an invalid result.
Chlamydia trichomitis detection using BD ProbeTec TM ET Chlamydia trachomatis amplifi ed DNA assay
The BD ProbeTec TM ET Chlamydia trachomatis amplifi ed DNA assay is based on the simultaneous amplifi cation and detection of target Deoxyrobonucleic Acid (DNA) using amplifi cation primers and a fl uorescent labeled detector probe. The BD ProbeTec TM ET Chlamydia trachomatis (CT) Amplifi ed DNA Assay, when tested with the BD ProbeTec ET System, uses Strand Displacement Amplifi cation (SDA) technology for the direct, qualitative detection of Chlamydia trachomatis DNA in endocervical swabs. The detection procedure was performed according to the manufacturer's instructions. Briefl y, each swab was inserted into a tube with 1 ml of the diluents and mixed by swirling to extract the endocervical secretion from the swab. The contents were vortexed for 5 seconds to mix the fl uid and the sample. After vortexing the tubes were placed on the lysing rack, locked into position lysed at 114°C for 30 minutes. After lysing, the tubes were left 25°C for 15 minutes to cool.
After cooling, 150 μl of lysed sample was transferred to the priming microwells using a multi-channel micropipette. The priming plate was covered with a priming cover and incubated at 25°C for 20 minutes. After 20 minutes of incubation, the priming microwells with the cover removed and empty amplifi cation microwells plates were placed in priming/warming heater (set at 72.5°C and 54°C) respectively. The plates were incubated for 10 minutes. At the end of the 10 minutes, 100 μl was transferred to the corresponding amplifi cation microwells. Immediately after the transfer, the amplifi cation microwells were sealed with an amplifi cation sealer and placed into instrument. The instrument was immediately activated for automated amplifi cation and detection of target DNA for 60 minutes. Interpretation of the test results was done automatically by the instrument according to method other than acceleration (MOTA) scores.
Treatment
Those who tested positive with either of the two tests were put on a 7-day treatment course of erythromycin, 500mg four times daily, by ANC midwives.
Statistical data analysis
Descriptive summary statistics of the data were obtained using Stata version 12 statistical software. Univariate logistic regression analysis (p<0.05 at 95% confi dence interval (C.I) was performed to identify factors associated with C. trachomatis infection and multivariate analysis (p<0.05 at 95% C.I) was performed to adjust for confounding risk factors associated with C. trachomatis infection. The performance characteristics, including sensitivity, specifi city, and positive and negative predictive values were calculated by standard methods.
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Ethical considerations
Ethical approval was obtained from the Joint Research Ethics Committee (JREC) and the Harare City Health Department. Participants were given informed consent forms written in the language they preferred between English and vernacular (Shona). Signed informed consent forms and the results were kept in custody by the researcher. anonymous identity numbers were used on the samples to conceal the participants' identities. Participants were also informed that their participation was voluntary and that they could decline to answer certain questions, including that they could withdraw their participation at any time without affecting the care they receive at the clinic.
Results
Characteristics of the study participants
Two hundred and forty two pregnant women with a median gestation age of 30 (IQR: 26-34) weeks were enrolled to participate in the study. They had a median age of 25 (IQR: 21-31) years. Two hundred and thirty seven (98%) of the women were married. Thirty (12%) of these women had previously been treated for STI.
Prevalence of C. trachomatis in the study participants
Using the SDA reference method, 14/242 (5.8%) of the women had positive results for C. trachomatis, while 11/242 (4.6%) of the women tested positive for C. trachomatis using the rapid test method. However, the results of the two tests were not statistically different (p=0.683).
Notably, the positivity rate in 18-25 age group was 6.6% using the rapid test and 7.4% using the SDA reference method. In addition, the 26-30 age had a positivity rate of 3.8% using the rapid method and 5.8% using the SDA reference method. Those aged above 30 years had a positivity rate of 1.5% using the rapid test and 2.9% using the reference method. All women who tested positive for C. trachomatis with both tests were married.
Women in the fi rst trimester had a similar positivity rate of 11.1% using the reference method and the rapid method. However, women in the second trimester had positivity rates of 9.5% and 7.9% using the reference and the rapid method, respectively. Women in the third trimester had the least positivity rates of 4.1% and 2.4% using the reference and the rapid method, respectively. However, the positivity rates were not statistically different between the semesters (p=0.229). Table 1 presents results of logistic regression analysis of factors associated with C. trachomatis infection in the pregnant women. When adjusted for other factors, the 18-25 age group was 2.7 times more likely to be positive for chlamydial infection when compared to the ages above 30. However, age was not a statistically signifi cant predictor of chlamydial infection (p> 0.05). The 26-30 age group had a lower risk of infection (OR=2.1) compared to the ages above 30. When adjusted for other factors, being in the fi rst trimester was 2.8 times more likely to be infected with C. trachomatis CI (OR: 0.3 -26.4) when compared to being in the third trimester. 
Diagnostic capability of Cortez OneStep Chlamydia Rapi CardInsta test
Discussion
Prevalence of C. trachomatis
The results of this study by the rapid (4.6%) and the reference method (5.8%) were not statistically different. This implies that the Cortez OneStep Chlamydia RapiCard TM Insta test is a valuable test for the detection of C. trachomatis in this population. These fi ndings corroborate those of other studies reviewed by Wilson et al [17] and other studies in Africa. [1, [18] [19] [20] These studies reported prevalence of C. trachomatis infection ranging from 3 to 31% in sub-Saharan Africa. Munjoma et al reported a seroprevalence of C. trachomatis of 4.1% in HSV-2 infected pregnant adolescent women. [21] Women in the 18-25 age group had higher prevalence (7.4%) compared to the 26-30 age group which had a prevalence rate of 5.8%. According to Mayaud et al, younger age is an important factor associated with C. trachomatis infection. [22] This implies that age needs to be considered in screening programmes for C. trachomatis. De Muylder et al reported that the presence of chlamydial antibodies were higher in older ages. [23] In relation to marital status in this group, only married women tested positive for chlamydia. The same was for a study done in Nigeria, where married women had higher prevalence (38.4%) compared to the unmarried women. [24] Women in the fi rst trimester tested positive (11.1%).This emphasizes the need to screen for C. trachomatis during the fi rst ANC visit, and repeat the test only in the third trimester as recommended by the CDC.
[25] There is need to encourage pregnant women to register early for ANC. The low prevalence in the third trimester may be due to use of antimicrobial agents such as amoxycillin to treat other infections. Only two of the women who tested positive for C. trachomatis had a history STIs. As also shown in a study by JavatoLaxer and colleagues, previous STI did not appear to increase the risk for C. trachomatis infection. [5] 
Performance of Cortez OneStep Chlamydia RapiCard TM insta test
The Cortez OneStep Chlamydia RapiCardInsta Test correctly detected 71.4% of pregnant women with C. trachomatis infection and 99.6% of those without the infection. This implies that it is an important test for the detection of genital chlamydia infection.
The high NPV of 98.3% means that by using the rapid test in diagnosis of C. trachomatis in pregnant women, the majority of those with no C. trachomatis infection will be correctly identifi ed. However the lower PPV of 90.9% means a relatively lower probability of detecting those pregnant women with the infection than when SDA is used.
The sensitivity of the Cortez OneStep Chlamydia RapiCardInsta test in this study was less (71.4%) than that the rate reported in the manufacturer's package insert of 97.2%. The difference in the sensitivity reported in this study may be due to the comparison of the Cortez OneStep Chlamydia RapiCardInsta Test with SDA. The manufacturers used the latex OneStep immunoassay as the gold standard. The manufacturer's sensitivity claims was higher than the values reported by other studies (3.3-18.8%). [26] The various rapid tests that have been evaluated for use in the diagnosis of C. trachomatis showed different sensitivities in detecting C. trachomatis. The sensitivity of 71.4% for Cortez OneStep Chlamydia test in this study was similar to the sensitivity of 73.8% demonstrated by the BioStar® OIA® CHLAYMDIA test. [27] Studies of other rapid tests in developing countries reported lower sensitivities, ranging from 49.7 to 53.5%. [16] QuickVue had a sensitivity of 92% when its performance was compared to NAAT. [14] In another study the sensitivity of QuickVue Chlamydia was 27% which is lower than the sensitivity reported in this study. [28] 
Limitations
We used a gold standard that is different from the one used by the manufacturer. This test was only evaluated for endocervical swab specimens from pregnant women. The sensitivity and specifi city of the test was not evaluated on urethral swabs or vaginal swabs. This evaluation was not conducted using pure isolates of C. trachomatis.
Conclusions and Global Health Implications
The results of this study shows that the Cortez OneStep Chlamydia test is an important test which needs further evaluation before it can be used for routine screening of C. trachomatis infection. The prevalence of C. trachomatis in pregnant women in this population was 5.8% by SDA assay. Given the prevalence rate found in this study, there is need for our health policy makers to consider including screening for C. trachomatis in pregnant women attending ANC in Zimbabwe. With studies showing an increase in the prevalence of C. trachomatis in pregnant women, ranging from 2 to 35%, [20] and POC tests showing as high as 13.3% in Nigeria, [20] the introduction of POC tests for screening of C. trachomatis will improve the detection and timely treatment of the infection in asymptomatic pregnant women in resource limited countries like in subSaharan Africa. 
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Key Messages
• The prevalence of C. trachomatis found in this study (5.8%) was high.
• It is essential to screen for C. trachomatis at antenatal clinics in Zimbabwe.
• There is need to evaluate more point of care tests for affordability of screening of C. trachomatis in resource limited settings to fi nd a more sensitive and specifi c test.
